Switzerland-based Novartis will pay Xencor $150M up front in the agreement. The two companies will equally share the cost to jointly develop two Xencor antibodies as possible immunosuppressive therapies for cancer, according to a statement on Novartis’ website.
Novartis will additionally have the rights to develop and commercialize four more bispecific antibodies and use Xencor’s antibody technology in up to 10 additional molecules.
Xencor will retain full commercial rights in the U.S., while Novartis will receive commercial rights outside of the U.S.
More articles on supply chain:
Medtronic acquires HeartWare for $1.1B
Leukocyte reduction devices recalled for faulty filters
How Britain’s exit from the EU will affect the drug market
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
